Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 180 of 1,261
  1. US 11713324

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Neurocrine Biosciences, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  2. US 11713461

    Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  3. US 11713353

    Single-domain antibodies and variants thereof against PD-1

    Nanjing Legend Biotech Co., Ltd · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  4. US 11713292

    Treatment of cataplexy

    AXSOME MALTA LTD. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  5. US 11712418

    Chemoembolization agents

    The Regents of the University of California · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  6. US 11712474

    Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition

    Regen Biopharma, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  7. US 11712460

    Methods of treating chronic disorders with complement inhibitors

    Apellis Pharmaceuticals, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  8. US 11712461

    Long-acting polypeptide composition for treating atrial fibrillation and its application

    The First Affiliated Hospital of Xi'an Jiaotong University · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  9. WO 2023141408

    BÊTA-HYDROXY BÊTA-MÉTHYLBUTYRATE ET FLAVONOÏDE D'AGRUME POUR FAVORISER LA RÉGÉNÉRATION MUSCULAIRE

    ABBOTT LAB [US] · Granted Jul 27, 2023 · Expires Jul 22, 2043

    granted
  10. US 11707535

    Method and composition for treating neuropathic pain

    The Regents of the University of California · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  11. US 11708329

    Inhibitors of the WNT/beta-catenin pathway

    The Regents of the University of California · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  12. US 11708347

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  13. US 11708332

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  14. US 11709216

    Cardiac late gadolinium enhancement MRI for patients with implanted cardiac devices

    The Regents of the University of California · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  15. US 11708637

    Methods of supporting a graphene sheet disposed on a frame support

    The Regents of the University of California · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  16. US 11708423

    Chimeric engulfment receptor molecules and methods of use

    Cero Therapeutics Holdings, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  17. US 11707454

    Topical roflumilast formulation having antifungal properties

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  18. US 11707434

    Method for preparing organic solvent-free lyophilized cyclophosphamide

    KOREA UNITED PHARM. INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  19. US 11707503

    Modulators of complement activity

    RA PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  20. US 11707346

    Dental mill blank and method for producing same

    KURARAY NORITAKE DENTAL INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  21. US 11708333

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  22. US 11707506

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  23. US 11708415

    Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  24. US 11708406

    Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody

    AVALO THERAPEUTICS, INC. · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.